A comparative study of panipenem/betamipron and imipenem/cilastatin in bacterial pneumonia

Kohei Hara; Yomei Hiraga; Mitsuhide Omichi; Kazuo Takebe; Mitsuo Masuda; Seiichi Murakami; Masakatsu Matsukawa; Gen Fukushi; Hisashi Nakahata; Tsukasa Yoshida; Toshiharu Ito; Masaaki Arakawa; Koichi Wada; Takashi Kawashima; Masanaga Takato; Fumihide Iwata; Naoki Osaki; Gen Takeda; Osamu Sekine; Yasutoshi Suzuki; Saburo Izumi; Masataka Katsu; Akira Oishi; Shinichi Enomoto; Masaru Koyama; Kaoru Shimada; Osamu Sakai; Jingoro Shimada; Kohya Shiba; Masaki Yoshida; Hiroichi Tanimoto; Kazuo Obara; Hiroyuki Kobayashi; Shoichiro Irimajiri; Yasuo Matsuoka; Mitsuo Obana; Fumio Matsumoto; Kaoru Shimokata; Syuzo Sakai; Yoshihiro Senda; Yoshio Torii; Masashi Yamamoto; Keisuke Nishiwaki; Hiroshi Saito; Kojiro Yasunaga; Seibun Yonezu; Kouichiro Ida; Yoshihiro Ueda; Fumio Miki; Nobuhiro Narita; Masayoshi Sawaki; Keiichi Mikasa; Susumu Kishimoto; Tomiya Masuno; Takahiko Yoshimoto; Hideki Hara; Masami Ito; Naoyoshi Koujiro; Toshiyuki Ikeda; Norio Ochi; Tetsuya Ogawa; Toru Sasaki; Akemi Numamoto; Tsuyoshi Igarashi; Kiyoshi Komuta; Keiji Maeda; Eiro Tsubura; Masaru Nakagawa; Rinzo Soejima; Masaru Sumi; Toshiharu Matsushima; Makoto Kimura; Masayasu Kawanishi; Makoto Kurimura; Hideo Sasaki; Kikuo Nakano; Akimasa Ohune; Takaaki Matsui; Koutaro Ohizumi; Youichiro Ichikawa; Michiya Matsunami; Masaharu Kinoshita; Eiichi Higuchi; Keizo Matsumoto; Yoshiro Araki; Masayuki Ando; Kazuko Sakata; Atsushi Saito; Yoshiteru Shigeno; Yuei Irabu; Hiroshi Fukuhara; Osamu Zaha; Jun Inatome; Mitsuyoshi Nakashima; Keizo Yamaguchi; Mitsuo Kaku; Kazuyuki Sugawara

doi:10.11250/chemotherapy1953.40.509

A comparative study of panipenem/betamipron and imipenem/cilastatin in bacterial pneumonia

Kohei Hara, Yomei Hiraga, Mitsuhide Omichi, Kazuo Takebe, Mitsuo Masuda, Seiichi Murakami, Masakatsu Matsukawa, Gen Fukushi, Hisashi Nakahata, Tsukasa Yoshida, Toshiharu Ito, Masaaki Arakawa, Koichi Wada, Takashi Kawashima, Masanaga Takato, Fumihide Iwata, Naoki Osaki, Gen Takeda, Osamu Sekine, Yasutoshi SuzukiSaburo Izumi, Masataka Katsu, Akira Oishi, Shinichi Enomoto, Masaru Koyama, Kaoru Shimada, Osamu Sakai, Jingoro Shimada, Kohya Shiba, Masaki Yoshida, Hiroichi Tanimoto, Kazuo Obara, Hiroyuki Kobayashi, Shoichiro Irimajiri, Yasuo Matsuoka, Mitsuo Obana, Fumio Matsumoto, Kaoru Shimokata, Syuzo Sakai, Yoshihiro Senda, Yoshio Torii, Masashi Yamamoto, Keisuke Nishiwaki, Hiroshi Saito, Kojiro Yasunaga, Seibun Yonezu, Kouichiro Ida, Yoshihiro Ueda, Fumio Miki, Nobuhiro Narita, Masayoshi Sawaki, Keiichi Mikasa, Susumu Kishimoto, Tomiya Masuno, Takahiko Yoshimoto, Hideki Hara, Masami Ito, Naoyoshi Koujiro, Toshiyuki Ikeda, Norio Ochi, Tetsuya Ogawa, Toru Sasaki, Akemi Numamoto, Tsuyoshi Igarashi, Kiyoshi Komuta, Keiji Maeda, Eiro Tsubura, Masaru Nakagawa, Rinzo Soejima, Masaru Sumi, Toshiharu Matsushima, Makoto Kimura, Masayasu Kawanishi, Makoto Kurimura, Hideo Sasaki, Kikuo Nakano, Akimasa Ohune, Takaaki Matsui, Koutaro Ohizumi, Youichiro Ichikawa, Michiya Matsunami, Masaharu Kinoshita, Eiichi Higuchi, Keizo Matsumoto, Yoshiro Araki, Masayuki Ando, Kazuko Sakata, Atsushi Saito, Yoshiteru Shigeno, Yuei Irabu, Hiroshi Fukuhara, Osamu Zaha, Jun Inatome, Mitsuyoshi Nakashima, Keizo Yamaguchi, Mitsuo Kaku, Kazuyuki Sugawara

MED - Medical Sciences

Research output: Contribution to journal › Article › peer-review

9 Citations (Scopus)

Abstract

With the aim of objectively evaluating the efficacy, safety and usefulness of panipenem/betamipron (PAPM/BP) in the treatment of bacterial pneumonia, a comparative study using imipenem/cilastatin sodium (IPM/CS) as the control drug was undertaken, and the following results obtained. Either PAPM/BP or IPM/CS, in a dose of 1.0 g/1.0 g daily (in 2 divided doses), was administered for a duration of, in principle, 14 days. 1) Clinical efficacy: The efficacy rate in the judgement of the committee was 84.5% in the PAPM/BP group and 91.1% in the IPM/CS group, with no significant difference between the two groups. Judged by the physician in charge, the rate was 85.9% in the PAPM/BP group and 82.1% in the IPM/CS group, with no significant difference between the two groups. 2) Bacteriological efficacy: The eradication rate was 78.3% in the PAPM/BP group and 100% in the IPM/CS group, with no significant difference between the two groups. 3) Side effects and abnormal laboratory data: The incidence of side effects was 3.6% in the PAPM/BP group and 5.7% in the IPM/CS group. Abnormal laboratory data were found in 39.5% and 26.5% respectively, but none was serious and no significant difference was seen between the two groups. 4) Usefulness: The rate of usefulness was evaluated by the committee to be 83.1% in the PAPM/BP group and 85.7% in the IPM/CS group, with no significant difference between the two groups. Judged by the physician in charge, the rate was 84.5% in the PAPM/BP group and 83.6% in the IPM/CS group, with no significant difference between the two groups. These results confirm that the administration of PAPM/BP, 1.0 g/1.0 g daily in the treatment of bacterial pneumonia is as clinically useful as the administration of IPM/CS, 1.0 g/1.0 g daily.

Original language	English
Pages (from-to)	509-531
Number of pages	23
Journal	Chemotherapy
Volume	40
Issue number	4
DOIs	https://doi.org/10.11250/chemotherapy1953.40.509
Publication status	Published - 1992 Apr

Keywords

Bacterial pneumonia
Comparative study
IPM/CS
PAPM/BP
panipenem/betamipron

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

Access to Document

10.11250/chemotherapy1953.40.509

Fingerprint Dive into the research topics of 'A comparative study of panipenem/betamipron and imipenem/cilastatin in bacterial pneumonia'. Together they form a unique fingerprint.

Cite this

Hara, K., Hiraga, Y., Omichi, M., Takebe, K., Masuda, M., Murakami, S., Matsukawa, M., Fukushi, G., Nakahata, H., Yoshida, T., Ito, T., Arakawa, M., Wada, K., Kawashima, T., Takato, M., Iwata, F., Osaki, N., Takeda, G., Sekine, O., ... Sugawara, K. (1992). A comparative study of panipenem/betamipron and imipenem/cilastatin in bacterial pneumonia. Chemotherapy, 40(4), 509-531. https://doi.org/10.11250/chemotherapy1953.40.509

A comparative study of panipenem/betamipron and imipenem/cilastatin in bacterial pneumonia. / Hara, Kohei; Hiraga, Yomei; Omichi, Mitsuhide; Takebe, Kazuo; Masuda, Mitsuo; Murakami, Seiichi; Matsukawa, Masakatsu; Fukushi, Gen; Nakahata, Hisashi; Yoshida, Tsukasa; Ito, Toshiharu; Arakawa, Masaaki; Wada, Koichi; Kawashima, Takashi; Takato, Masanaga; Iwata, Fumihide; Osaki, Naoki; Takeda, Gen; Sekine, Osamu; Suzuki, Yasutoshi; Izumi, Saburo; Katsu, Masataka; Oishi, Akira; Enomoto, Shinichi; Koyama, Masaru; Shimada, Kaoru; Sakai, Osamu; Shimada, Jingoro; Shiba, Kohya; Yoshida, Masaki; Tanimoto, Hiroichi; Obara, Kazuo; Kobayashi, Hiroyuki; Irimajiri, Shoichiro; Matsuoka, Yasuo; Obana, Mitsuo; Matsumoto, Fumio; Shimokata, Kaoru; Sakai, Syuzo; Senda, Yoshihiro; Torii, Yoshio; Yamamoto, Masashi; Nishiwaki, Keisuke; Saito, Hiroshi; Yasunaga, Kojiro; Yonezu, Seibun; Ida, Kouichiro; Ueda, Yoshihiro; Miki, Fumio; Narita, Nobuhiro; Sawaki, Masayoshi; Mikasa, Keiichi; Kishimoto, Susumu; Masuno, Tomiya; Yoshimoto, Takahiko; Hara, Hideki; Ito, Masami; Koujiro, Naoyoshi; Ikeda, Toshiyuki; Ochi, Norio; Ogawa, Tetsuya; Sasaki, Toru; Numamoto, Akemi; Igarashi, Tsuyoshi; Komuta, Kiyoshi; Maeda, Keiji; Tsubura, Eiro; Nakagawa, Masaru; Soejima, Rinzo; Sumi, Masaru; Matsushima, Toshiharu; Kimura, Makoto; Kawanishi, Masayasu; Kurimura, Makoto; Sasaki, Hideo; Nakano, Kikuo; Ohune, Akimasa; Matsui, Takaaki; Ohizumi, Koutaro; Ichikawa, Youichiro; Matsunami, Michiya; Kinoshita, Masaharu; Higuchi, Eiichi; Matsumoto, Keizo; Araki, Yoshiro; Ando, Masayuki; Sakata, Kazuko; Saito, Atsushi; Shigeno, Yoshiteru; Irabu, Yuei; Fukuhara, Hiroshi; Zaha, Osamu; Inatome, Jun; Nakashima, Mitsuyoshi; Yamaguchi, Keizo; Kaku, Mitsuo; Sugawara, Kazuyuki.

In: Chemotherapy, Vol. 40, No. 4, 04.1992, p. 509-531.

Research output: Contribution to journal › Article › peer-review

Hara, K, Hiraga, Y, Omichi, M, Takebe, K, Masuda, M, Murakami, S, Matsukawa, M, Fukushi, G, Nakahata, H, Yoshida, T, Ito, T, Arakawa, M, Wada, K, Kawashima, T, Takato, M, Iwata, F, Osaki, N, Takeda, G, Sekine, O, Suzuki, Y, Izumi, S, Katsu, M, Oishi, A, Enomoto, S, Koyama, M, Shimada, K, Sakai, O, Shimada, J, Shiba, K, Yoshida, M, Tanimoto, H, Obara, K, Kobayashi, H, Irimajiri, S, Matsuoka, Y, Obana, M, Matsumoto, F, Shimokata, K, Sakai, S, Senda, Y, Torii, Y, Yamamoto, M, Nishiwaki, K, Saito, H, Yasunaga, K, Yonezu, S, Ida, K, Ueda, Y, Miki, F, Narita, N, Sawaki, M, Mikasa, K, Kishimoto, S, Masuno, T, Yoshimoto, T, Hara, H, Ito, M, Koujiro, N, Ikeda, T, Ochi, N, Ogawa, T, Sasaki, T, Numamoto, A, Igarashi, T, Komuta, K, Maeda, K, Tsubura, E, Nakagawa, M, Soejima, R, Sumi, M, Matsushima, T, Kimura, M, Kawanishi, M, Kurimura, M, Sasaki, H, Nakano, K, Ohune, A, Matsui, T, Ohizumi, K, Ichikawa, Y, Matsunami, M, Kinoshita, M, Higuchi, E, Matsumoto, K, Araki, Y, Ando, M, Sakata, K, Saito, A, Shigeno, Y, Irabu, Y, Fukuhara, H, Zaha, O, Inatome, J, Nakashima, M, Yamaguchi, K, Kaku, M & Sugawara, K 1992, 'A comparative study of panipenem/betamipron and imipenem/cilastatin in bacterial pneumonia', Chemotherapy, vol. 40, no. 4, pp. 509-531. https://doi.org/10.11250/chemotherapy1953.40.509

Hara, Kohei ; Hiraga, Yomei ; Omichi, Mitsuhide ; Takebe, Kazuo ; Masuda, Mitsuo ; Murakami, Seiichi ; Matsukawa, Masakatsu ; Fukushi, Gen ; Nakahata, Hisashi ; Yoshida, Tsukasa ; Ito, Toshiharu ; Arakawa, Masaaki ; Wada, Koichi ; Kawashima, Takashi ; Takato, Masanaga ; Iwata, Fumihide ; Osaki, Naoki ; Takeda, Gen ; Sekine, Osamu ; Suzuki, Yasutoshi ; Izumi, Saburo ; Katsu, Masataka ; Oishi, Akira ; Enomoto, Shinichi ; Koyama, Masaru ; Shimada, Kaoru ; Sakai, Osamu ; Shimada, Jingoro ; Shiba, Kohya ; Yoshida, Masaki ; Tanimoto, Hiroichi ; Obara, Kazuo ; Kobayashi, Hiroyuki ; Irimajiri, Shoichiro ; Matsuoka, Yasuo ; Obana, Mitsuo ; Matsumoto, Fumio ; Shimokata, Kaoru ; Sakai, Syuzo ; Senda, Yoshihiro ; Torii, Yoshio ; Yamamoto, Masashi ; Nishiwaki, Keisuke ; Saito, Hiroshi ; Yasunaga, Kojiro ; Yonezu, Seibun ; Ida, Kouichiro ; Ueda, Yoshihiro ; Miki, Fumio ; Narita, Nobuhiro ; Sawaki, Masayoshi ; Mikasa, Keiichi ; Kishimoto, Susumu ; Masuno, Tomiya ; Yoshimoto, Takahiko ; Hara, Hideki ; Ito, Masami ; Koujiro, Naoyoshi ; Ikeda, Toshiyuki ; Ochi, Norio ; Ogawa, Tetsuya ; Sasaki, Toru ; Numamoto, Akemi ; Igarashi, Tsuyoshi ; Komuta, Kiyoshi ; Maeda, Keiji ; Tsubura, Eiro ; Nakagawa, Masaru ; Soejima, Rinzo ; Sumi, Masaru ; Matsushima, Toshiharu ; Kimura, Makoto ; Kawanishi, Masayasu ; Kurimura, Makoto ; Sasaki, Hideo ; Nakano, Kikuo ; Ohune, Akimasa ; Matsui, Takaaki ; Ohizumi, Koutaro ; Ichikawa, Youichiro ; Matsunami, Michiya ; Kinoshita, Masaharu ; Higuchi, Eiichi ; Matsumoto, Keizo ; Araki, Yoshiro ; Ando, Masayuki ; Sakata, Kazuko ; Saito, Atsushi ; Shigeno, Yoshiteru ; Irabu, Yuei ; Fukuhara, Hiroshi ; Zaha, Osamu ; Inatome, Jun ; Nakashima, Mitsuyoshi ; Yamaguchi, Keizo ; Kaku, Mitsuo ; Sugawara, Kazuyuki. / A comparative study of panipenem/betamipron and imipenem/cilastatin in bacterial pneumonia. In: Chemotherapy. 1992 ; Vol. 40, No. 4. pp. 509-531.

@article{cf1181c11d8046dbbbd272c462ef214a,

title = "A comparative study of panipenem/betamipron and imipenem/cilastatin in bacterial pneumonia",

abstract = "With the aim of objectively evaluating the efficacy, safety and usefulness of panipenem/betamipron (PAPM/BP) in the treatment of bacterial pneumonia, a comparative study using imipenem/cilastatin sodium (IPM/CS) as the control drug was undertaken, and the following results obtained. Either PAPM/BP or IPM/CS, in a dose of 1.0 g/1.0 g daily (in 2 divided doses), was administered for a duration of, in principle, 14 days. 1) Clinical efficacy: The efficacy rate in the judgement of the committee was 84.5% in the PAPM/BP group and 91.1% in the IPM/CS group, with no significant difference between the two groups. Judged by the physician in charge, the rate was 85.9% in the PAPM/BP group and 82.1% in the IPM/CS group, with no significant difference between the two groups. 2) Bacteriological efficacy: The eradication rate was 78.3% in the PAPM/BP group and 100% in the IPM/CS group, with no significant difference between the two groups. 3) Side effects and abnormal laboratory data: The incidence of side effects was 3.6% in the PAPM/BP group and 5.7% in the IPM/CS group. Abnormal laboratory data were found in 39.5% and 26.5% respectively, but none was serious and no significant difference was seen between the two groups. 4) Usefulness: The rate of usefulness was evaluated by the committee to be 83.1% in the PAPM/BP group and 85.7% in the IPM/CS group, with no significant difference between the two groups. Judged by the physician in charge, the rate was 84.5% in the PAPM/BP group and 83.6% in the IPM/CS group, with no significant difference between the two groups. These results confirm that the administration of PAPM/BP, 1.0 g/1.0 g daily in the treatment of bacterial pneumonia is as clinically useful as the administration of IPM/CS, 1.0 g/1.0 g daily.",

keywords = "Bacterial pneumonia, Comparative study, IPM/CS, PAPM/BP, panipenem/betamipron",

author = "Kohei Hara and Yomei Hiraga and Mitsuhide Omichi and Kazuo Takebe and Mitsuo Masuda and Seiichi Murakami and Masakatsu Matsukawa and Gen Fukushi and Hisashi Nakahata and Tsukasa Yoshida and Toshiharu Ito and Masaaki Arakawa and Koichi Wada and Takashi Kawashima and Masanaga Takato and Fumihide Iwata and Naoki Osaki and Gen Takeda and Osamu Sekine and Yasutoshi Suzuki and Saburo Izumi and Masataka Katsu and Akira Oishi and Shinichi Enomoto and Masaru Koyama and Kaoru Shimada and Osamu Sakai and Jingoro Shimada and Kohya Shiba and Masaki Yoshida and Hiroichi Tanimoto and Kazuo Obara and Hiroyuki Kobayashi and Shoichiro Irimajiri and Yasuo Matsuoka and Mitsuo Obana and Fumio Matsumoto and Kaoru Shimokata and Syuzo Sakai and Yoshihiro Senda and Yoshio Torii and Masashi Yamamoto and Keisuke Nishiwaki and Hiroshi Saito and Kojiro Yasunaga and Seibun Yonezu and Kouichiro Ida and Yoshihiro Ueda and Fumio Miki and Nobuhiro Narita and Masayoshi Sawaki and Keiichi Mikasa and Susumu Kishimoto and Tomiya Masuno and Takahiko Yoshimoto and Hideki Hara and Masami Ito and Naoyoshi Koujiro and Toshiyuki Ikeda and Norio Ochi and Tetsuya Ogawa and Toru Sasaki and Akemi Numamoto and Tsuyoshi Igarashi and Kiyoshi Komuta and Keiji Maeda and Eiro Tsubura and Masaru Nakagawa and Rinzo Soejima and Masaru Sumi and Toshiharu Matsushima and Makoto Kimura and Masayasu Kawanishi and Makoto Kurimura and Hideo Sasaki and Kikuo Nakano and Akimasa Ohune and Takaaki Matsui and Koutaro Ohizumi and Youichiro Ichikawa and Michiya Matsunami and Masaharu Kinoshita and Eiichi Higuchi and Keizo Matsumoto and Yoshiro Araki and Masayuki Ando and Kazuko Sakata and Atsushi Saito and Yoshiteru Shigeno and Yuei Irabu and Hiroshi Fukuhara and Osamu Zaha and Jun Inatome and Mitsuyoshi Nakashima and Keizo Yamaguchi and Mitsuo Kaku and Kazuyuki Sugawara",

year = "1992",

month = apr,

doi = "10.11250/chemotherapy1953.40.509",

language = "English",

volume = "40",

pages = "509--531",

journal = "CHEMOTHERAPY",

issn = "0009-3165",

number = "4",

}

TY - JOUR

T1 - A comparative study of panipenem/betamipron and imipenem/cilastatin in bacterial pneumonia

AU - Hara, Kohei

AU - Hiraga, Yomei

AU - Omichi, Mitsuhide

AU - Takebe, Kazuo

AU - Masuda, Mitsuo

AU - Murakami, Seiichi

AU - Matsukawa, Masakatsu

AU - Fukushi, Gen

AU - Nakahata, Hisashi

AU - Yoshida, Tsukasa

AU - Ito, Toshiharu

AU - Arakawa, Masaaki

AU - Wada, Koichi

AU - Kawashima, Takashi

AU - Takato, Masanaga

AU - Iwata, Fumihide

AU - Osaki, Naoki

AU - Takeda, Gen

AU - Sekine, Osamu

AU - Suzuki, Yasutoshi

AU - Izumi, Saburo

AU - Katsu, Masataka

AU - Oishi, Akira

AU - Enomoto, Shinichi

AU - Koyama, Masaru

AU - Shimada, Kaoru

AU - Sakai, Osamu

AU - Shimada, Jingoro

AU - Shiba, Kohya

AU - Yoshida, Masaki

AU - Tanimoto, Hiroichi

AU - Obara, Kazuo

AU - Kobayashi, Hiroyuki

AU - Irimajiri, Shoichiro

AU - Matsuoka, Yasuo

AU - Obana, Mitsuo

AU - Matsumoto, Fumio

AU - Shimokata, Kaoru

AU - Sakai, Syuzo

AU - Senda, Yoshihiro

AU - Torii, Yoshio

AU - Yamamoto, Masashi

AU - Nishiwaki, Keisuke

AU - Saito, Hiroshi

AU - Yasunaga, Kojiro

AU - Yonezu, Seibun

AU - Ida, Kouichiro

AU - Ueda, Yoshihiro

AU - Miki, Fumio

AU - Narita, Nobuhiro

AU - Sawaki, Masayoshi

AU - Mikasa, Keiichi

AU - Kishimoto, Susumu

AU - Masuno, Tomiya

AU - Yoshimoto, Takahiko

AU - Hara, Hideki

AU - Ito, Masami

AU - Koujiro, Naoyoshi

AU - Ikeda, Toshiyuki

AU - Ochi, Norio

AU - Ogawa, Tetsuya

AU - Sasaki, Toru

AU - Numamoto, Akemi

AU - Igarashi, Tsuyoshi

AU - Komuta, Kiyoshi

AU - Maeda, Keiji

AU - Tsubura, Eiro

AU - Nakagawa, Masaru

AU - Soejima, Rinzo

AU - Sumi, Masaru

AU - Matsushima, Toshiharu

AU - Kimura, Makoto

AU - Kawanishi, Masayasu

AU - Kurimura, Makoto

AU - Sasaki, Hideo

AU - Nakano, Kikuo

AU - Ohune, Akimasa

AU - Matsui, Takaaki

AU - Ohizumi, Koutaro

AU - Ichikawa, Youichiro

AU - Matsunami, Michiya

AU - Kinoshita, Masaharu

AU - Higuchi, Eiichi

AU - Matsumoto, Keizo

AU - Araki, Yoshiro

AU - Ando, Masayuki

AU - Sakata, Kazuko

AU - Saito, Atsushi

AU - Shigeno, Yoshiteru

AU - Irabu, Yuei

AU - Fukuhara, Hiroshi

AU - Zaha, Osamu

AU - Inatome, Jun

AU - Nakashima, Mitsuyoshi

AU - Yamaguchi, Keizo

AU - Kaku, Mitsuo

AU - Sugawara, Kazuyuki

PY - 1992/4

Y1 - 1992/4

N2 - With the aim of objectively evaluating the efficacy, safety and usefulness of panipenem/betamipron (PAPM/BP) in the treatment of bacterial pneumonia, a comparative study using imipenem/cilastatin sodium (IPM/CS) as the control drug was undertaken, and the following results obtained. Either PAPM/BP or IPM/CS, in a dose of 1.0 g/1.0 g daily (in 2 divided doses), was administered for a duration of, in principle, 14 days. 1) Clinical efficacy: The efficacy rate in the judgement of the committee was 84.5% in the PAPM/BP group and 91.1% in the IPM/CS group, with no significant difference between the two groups. Judged by the physician in charge, the rate was 85.9% in the PAPM/BP group and 82.1% in the IPM/CS group, with no significant difference between the two groups. 2) Bacteriological efficacy: The eradication rate was 78.3% in the PAPM/BP group and 100% in the IPM/CS group, with no significant difference between the two groups. 3) Side effects and abnormal laboratory data: The incidence of side effects was 3.6% in the PAPM/BP group and 5.7% in the IPM/CS group. Abnormal laboratory data were found in 39.5% and 26.5% respectively, but none was serious and no significant difference was seen between the two groups. 4) Usefulness: The rate of usefulness was evaluated by the committee to be 83.1% in the PAPM/BP group and 85.7% in the IPM/CS group, with no significant difference between the two groups. Judged by the physician in charge, the rate was 84.5% in the PAPM/BP group and 83.6% in the IPM/CS group, with no significant difference between the two groups. These results confirm that the administration of PAPM/BP, 1.0 g/1.0 g daily in the treatment of bacterial pneumonia is as clinically useful as the administration of IPM/CS, 1.0 g/1.0 g daily.

AB - With the aim of objectively evaluating the efficacy, safety and usefulness of panipenem/betamipron (PAPM/BP) in the treatment of bacterial pneumonia, a comparative study using imipenem/cilastatin sodium (IPM/CS) as the control drug was undertaken, and the following results obtained. Either PAPM/BP or IPM/CS, in a dose of 1.0 g/1.0 g daily (in 2 divided doses), was administered for a duration of, in principle, 14 days. 1) Clinical efficacy: The efficacy rate in the judgement of the committee was 84.5% in the PAPM/BP group and 91.1% in the IPM/CS group, with no significant difference between the two groups. Judged by the physician in charge, the rate was 85.9% in the PAPM/BP group and 82.1% in the IPM/CS group, with no significant difference between the two groups. 2) Bacteriological efficacy: The eradication rate was 78.3% in the PAPM/BP group and 100% in the IPM/CS group, with no significant difference between the two groups. 3) Side effects and abnormal laboratory data: The incidence of side effects was 3.6% in the PAPM/BP group and 5.7% in the IPM/CS group. Abnormal laboratory data were found in 39.5% and 26.5% respectively, but none was serious and no significant difference was seen between the two groups. 4) Usefulness: The rate of usefulness was evaluated by the committee to be 83.1% in the PAPM/BP group and 85.7% in the IPM/CS group, with no significant difference between the two groups. Judged by the physician in charge, the rate was 84.5% in the PAPM/BP group and 83.6% in the IPM/CS group, with no significant difference between the two groups. These results confirm that the administration of PAPM/BP, 1.0 g/1.0 g daily in the treatment of bacterial pneumonia is as clinically useful as the administration of IPM/CS, 1.0 g/1.0 g daily.

KW - Bacterial pneumonia

KW - Comparative study

KW - IPM/CS

KW - PAPM/BP

KW - panipenem/betamipron

UR - http://www.scopus.com/inward/record.url?scp=0026776988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026776988&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.40.509

DO - 10.11250/chemotherapy1953.40.509

M3 - Article

AN - SCOPUS:0026776988

VL - 40

SP - 509

EP - 531

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

SN - 0009-3165

IS - 4

ER -

A comparative study of panipenem/betamipron and imipenem/cilastatin in bacterial pneumonia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this